Scott Koenig: We expect that most of the patients will €“ this will be in the castration resistant population we expect that most of the patients will be there. They may have seen, I believe, some chemo in the castration sensitive population, but expect to be a much smaller portion of that population.
Stephen Willey: Okay. And I think you touched upon it before, but I guess what’s the rationale for initiating this specific combination trial versus just waiting for combo data with vobra duo and then potentially resourcing that study instead?
Scott Koenig: Well, I think, first of all, we’re going to get our experience of combining this with the chemotherapy in a different chemotherapy. And as I pointed out earlier, Steve, that we see the prospects of this drug being used in very early lines, as well as late lines of therapy. So, I think this is our first foray into that. There’s no reason as we’re getting this data as we €“ if we identify a combo dose that looks good and can be moved forward that independently we can develop another trial using that combo. So, it’s not mutually exclusive.
Stephen Willey: Okay. Fair enough. And then I guess one of the assets to which you guys have some stake in and I don’t think was talked about earlier is the ImmunoGen ADC, IMGC936, I think. So, I think they said that they’ve initiated dose expansion now in lung and in triple negative. I think they’re going to have some data to share in 2Q. Can you just remind us what the next steps for this program might be from MacroGenics assuming that it does move forward beyond dose escalation? Is there a formal opt-in decision that you need to make just under the terms of the current agreement?
Scott Koenig: No, it’s €“ the way the deal is structured is it’s a 50-50, we €“ it’s a joint decision on both next steps the financing of the studies we actually have a very good relationship in terms of who would conduct the studies. And in the end, either of us could move forward there. And similarly, either of us could obviously opt-out and not choose to fund the study. I think that we still need some more time to look at the populations that ImmunoGen has disclosed of adding additional patients. I think on one of their last calls, they said that they are planning to add additional patients with lung cancer in the study and that would extend that further, but would provide an update. In the meantime, I think patients are being continuing to be followed at this point.
So, really nothing more to say right now. I think that finding the appropriate dose for treatment is the critical point here for continuing the study with other tumor type we both decide to move forward with.
Operator: Thank you. Our next question comes from Boris Peaker with Cowen. You may proceed.
Boris Peaker: Great. I have two questions. One on lorigerlimab and the other one on vobra. So, lorigerlimab, can you discuss how you decided on the dose for the Phase 2 trial and why you don’t think you need to have several doses like you were doing with vobra? And for vobra, how do you think will impact your ultimate Phase 3 trial design in TAMARACK of course?
Scott Koenig: Excellent questions, Boris. So, we as you know, dosed up to 10 mg per kg in the dose escalation study did not hit DLT. We did see increased new-related AEs at 10, so decided to continue at 6 mg per kg. As you know, on a Q3 weekly basis, as you know, we presented the safety data of 127 patients at ASCO-GU, which included the patients with prostate cancer as well as other tumor types in that safety analysis. We believe that 6 mg per kg is an active and safe dose. But the beauty of this molecule, if you recall the data from the dose escalation study, we had a 100% full occupancy of PD-1 positive cells at 1 mg per kg and higher. We were seeing objective responses at 3 mg per kg and higher. We were seeing evidence of biomarker activity based on and CD4s and CD8s and on CD4s as those lower doses as well as the 103 mg per kg.
